Fisher & Paykel Healthcare Corporation Limited logo

Ongoing Disclosure Notice – Dividend Reinvestment Plan

Insider Disclosure27 December 2022FPHHealthcare

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer:

Fisher & Paykel Healthcare Corporation Limited

Date this disclosure made:

23 December 2022

Date of last disclosure:

30 August 2022

Director or senior manager giving disclosure

Full name(s):

Scott Andrew St John

Name of listed issuer:

Fisher & Paykel Healthcare Corporation Limited

Name of related body corporate (if applicable):

Position held in listed issuer:

Director

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:

Ordinary Shares

Nature of the affected relevant interest(s):

Beneficial interest in Ordinary Shares

For that relevant interest

Number held in class before acquisition or disposal:

22,000

Number held in class after acquisition or disposal:

22,178

Current registered holder(s):

FNZ Custodians as Custodian for Scott Andrew St John

Registered holder(s) once transfers are registered:

FNZ Custodians as Custodian for Scott Andrew St John

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:

Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial

products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative(if any):

The price specified in the terms of the derivative (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the underlying

financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant

interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

One

Details of transactions requiring disclosure-

Date of transaction:

21 December 2022

Nature of transaction:
Purchase of Ordinary Shares under the Company's dividend

reinvestment plan

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition

or disposal. If the consideration was not in cash and cannot be readily by converted into a

cash value, describe the consideration:

NZD 21.6750 per share (this is the DRP strike price which is

inclusive of the 3% discount)

Number of financial products to which the transaction related:

178

If the issuer has a financial products trading policy that prohibits directors or senior

managers from trading during any period without written clearance (a closed period)

include the following details—

Whether relevant interests were aquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the aquisition or disposal to

proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial

products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the underlying

financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant

interest in the derivative:

Cerification

I certify that, to the best of my knowledge and belief, the information contained in this

disclosure is correct and that I am duly authorised to make this disclosure by all persons

for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:23 December 2022

Name and title of authorised person:Raelene Leonard, Company Secretary

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • TAH — Third Age Health Services Limited: D&O Ongoing Disclosure Notice
    2023-01-23

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Third Age Health Services Limited Date this disclosure made: 24 January 2023 Date…”

  • TAH — Third Age Health Services Limited: D&O Ongoing Disclosure Notice
    2023-01-26

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Third Age Health Services Limited Date this disclosure made: 27 January 2023 Date…”

  • FBU — Fletcher Building: D&O Ongoing Disclosures – Multiple
    2023-03-23

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Fletcher Building Limited Date this disclosure made:23 March 2023 Date of last disc…”